OTCMKTS:OTLC

Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

$0.04
0.00 (0.00%)
(As of 04/23/2024 ET)
Today's Range
$0.04
$0.04
50-Day Range
$0.04
$0.04
52-Week Range
$0.01
$0.05
Volume
8,356 shs
Average Volume
75,335 shs
Market Capitalization
$14.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OTLC stock logo

About Oncotelic Therapeutics Stock (OTCMKTS:OTLC)

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

OTLC Stock Price History

OTLC Stock News Headlines

Linkage of Cancer and Lupus in Gliomas Patients
Linkage of Cancer and Lupus in Gliomas Patients
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Invitation to Participate in STOP-PC Clinical Trial
Lineage Cell Therapeutics Inc LCTX
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Oncotelic Therapeutics reports Q3 results
Oncotelic Launches PDAO SEC Chatbot
Oncotelic Therapeutics reports FY results
OTLC Oncotelic Therapeutics, Inc.
Oncotelic Issues Year End Message to Shareholders
See More Headlines
Receive OTLC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/19/2021
Today
4/24/2024
Next Earnings (Estimated)
5/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:OTLC
Employees
22
Year Founded
N/A

Profitability

Net Income
$-7,900,000.00
Pretax Margin
-11,722.86%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Cash Flow
$0.01 per share
Book Value
$0.03 per share

Miscellaneous

Free Float
242,309,000
Market Cap
$14.35 million
Optionable
Not Optionable
Beta
0.13
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Vuong Trieu Ph.D. (Age 61)
    Chairman & CEO
    Comp: $75.5k
  • Mr. Amit Shah (Age 57)
    Chief Financial Officer
    Comp: $40.44k
  • Dr. Anthony E. Maida III (Age 72)
    B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director
    Comp: $75k
  • Mr. Saranjit Saund (Age 66)
    CBO & GM of AI Division
    Comp: $35.43k
  • Mr. Steven W. King (Age 60)
    Consultant & Director
  • Dr. Larn Hwang (Age 61)
    Chief Scientific Officer
  • Dr. Seymour Howard Fein M.D. (Age 75)
    Chief Medical Officer
  • Mr. Burcak Beser
    CTO of AI Division

OTLC Stock Analysis - Frequently Asked Questions

How have OTLC shares performed in 2024?

Oncotelic Therapeutics' stock was trading at $0.0383 at the beginning of 2024. Since then, OTLC shares have decreased by 6.0% and is now trading at $0.0360.
View the best growth stocks for 2024 here
.

Are investors shorting Oncotelic Therapeutics?

Oncotelic Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 400 shares, a decline of 89.7% from the March 15th total of 3,900 shares. Based on an average trading volume of 136,800 shares, the short-interest ratio is currently 0.0 days.
View Oncotelic Therapeutics' Short Interest
.

When is Oncotelic Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024.
View our OTLC earnings forecast
.

How were Oncotelic Therapeutics' earnings last quarter?

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) posted its quarterly earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02.

How do I buy shares of Oncotelic Therapeutics?

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OTLC) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners